The clinical significanceof IL-6 in non-small cell lung cancer

• Main Authors: Shine-Yuan Chung, 鍾劦媛
• Other Authors: 周寬基
• Format: Others
• Language: zh-TW
• Published: 2006
• Online Access: http://ndltd.ncl.edu.tw/handle/18954598552089895797

碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 94 === Interleukin-6 (IL-6) plays an important role in the proliferation of cancer cells and correlates with disease progression and prognosis. In this study we identified the source and the clinical roles of IL-6 in non-small cell lung cancer (NSCLC).Tissue specimens were collected from 59 patients undergone surgery for NSCLC. Detection of IL-6 mRNA was determined by in situ hybridization (ISH) and reverse transcription polymerase chain reaction (RT-PCR). Expression of IL-6 protein was identified by immunohistochemical staining (IHC). IL-6 mRNA was identified by ISH in non-tumor parts (n=43; 50.84%) and tumor parts (n=16; 27.11%) and expression IL-6 mRNA was correlated with patients，survival. Semi-quantitative RT-PCR confirmed IL-6 mRNA was mainly produced by non-tumor cells. IL-6 protein was identified in non-tumor parts (n=38; 64.4%) and tumor parts (n=11;18.64%). Tumor associated macrophages (TAM) and tumor infiltrating lymphocytes (TIL) were two major source producing IL-6. We further used CD68 antibody in immune staining to differential TAM and TIL at the same time. We confirmed that tumor infiltrating lymphocytes were the major sources of IL-6 in NSCLC. These results show that IL-6 in NSCLC, non-tumor parts express higher IL-6 mRNA and protein than tumor parts, especially tumor infiltrating lymphocytes. Patients with NSCLC, expressing high levels IL-6 mRNA associated with good prognosis.